Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
Rodrigo Fonseca(WinnMed), Rafaël Fonseca(Mayo Clinic in Arizona), P. Leif Bergsagel(Mayo Clinic in Arizona), Mariano Arribas(Mayo Clinic Hospital), A. Keith Stewart(Princess Margaret Hospital), Ilan R. Kirsch(Adaptive Biotechnologies (United States)), Miguel González-Vélez(Mayo Clinic Hospital), Heidi Kosiorek(Mayo Clinic in Florida), Joseph Mıkhael(Translational Genomics Research Institute), Yael Kusne(WinnMed), Julia E. Wiedmeier(Mayo Clinic Hospital), Richard Butterfield(Adaptive Biotechnologies (United States)), Craig B. Reeder(Mayo Clinic in Arizona), Jeremy T. Larsen(City of Hope)
Cited by 3
Related Papers
Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells.
|Proceedings of the National Academy of Sciences|1982|1.4k
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k